胰高血糖素样肽1受体
胰高血糖素受体
脂肪性肝炎
受体
痛苦
兴奋剂
内分泌学
医学
纤维化
肝纤维化
胰高血糖素
药理学
内科学
胰岛素
脂肪肝
疾病
政治
政治学
法学
作者
Arun J. Sanyal,Pierre Bédossa,Mandy Fraessdorf,Guy Neff,Eric Lawitz,Elisabetta Bugianesi,Quentin M. Anstee,Samina Ajaz Hussain,Philip N. Newsome,Vlad Ratziu,Azadeh Hosseini‐Tabatabaei,Jörn M. Schattenberg,Mazen Noureddin,Naim Alkhouri,Ramy Younes
标识
DOI:10.1056/nejmoa2401755
摘要
Dual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor may be more effective than GLP-1 receptor agonism alone for treating metabolic dysfunction-associated steatohepatitis (MASH). The efficacy and safety of survodutide (a dual agonist of glucagon receptor and GLP-1 receptor) in persons with MASH and liver fibrosis are unclear.
科研通智能强力驱动
Strongly Powered by AbleSci AI